Stock Events

Oncocyte 

$3.17
0
+$0.13+4.35% Wednesday 14:21

Statistics

Day High
3.17
Day Low
3.17
52W High
4.23
52W Low
0.21
Volume
10
Avg. Volume
382
Mkt Cap
26.59B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7NovExpected
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Next
-1.01
-0.7
-0.39
-0.08
Expected EPS
-0.436667
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0KCC.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Show more...
CEO
Mr. Joshua Riggs
Employees
43
Country
US
ISIN
US68235C2061

Listings